Members Sign In
Members Sign InAll | Clinical Notices | General Notices | Vacancies
These are generally targeted at undergraduate, honours and/or masters students who have not yet completed their degree.
Projects must be diabetes related and appropriate supervision needs to be provided by the host institution.
Applications open on 7th July 2025 and must be submitted via the NZSSD website
by 5pm, Friday the 15th of August 2025.
For further information about research grants please contact the NZSSD Secretariat Secretary@nzssd.org.nz
Grant or research-specific questions may also be directed to A/Prof Hamish Crocket hamish.crocket@waikato.ac.nz
Kia ora koutou
I am very pleased to share this news about access to GLP1a dulaglutide.
From 1 July 2025, Pharmac is removing the 'no new patient restriction' on the GLP1a dulaglutide (branded as Trulicity). This means people with type 2 diabetes, who meet the eligibility criteria, will be able to start on treatment with this medicine.
More information about the ongoing supply issue is available on the Pharmac website: Dulaglutide(Trulicity) and Liraglutide (Victoza): Supply issue
Please also visit the NZSSD Type 2 diabetes guidance for information on when/in which patients it is appropriate to prescribe a GLP1Ra, and prescribing and monitoring recommendations.
This is great news for people living with type 2 diabetes and the health professionals caring for them.
Ngā mihi nui
Jo
Dr Jo McClintock(she/her)
Consultant Clinical Psychologist |Kaimātai Hauora Hinengaro
President - New Zealand Society for the Study of Diabetes
NZSSD is currently accepting applications for the following grants:
1) Professional Development Award
There are eight awards available per year, two each quarter and are open to NZSSD financial members. The amount awarded will be at the discretion of the Executive with awards not usually more than $1,500 per individual. An award will be granted to an individual only once within a year.
This closes on 31 July, 2025. For more information and to apply click HERE
2) Registered Nurse Prescribing Development Grant 1 - for Semester 2, 2025
Registered Nurses, with a focus in diabetes care, working toward Registered Nurse Prescribing in Specialist and Primary Care Teams authorisation.
This closes on 4 July, 2025. For more information and to apply click HERE
3) Registered Nurse Prescribing Development Grant 2 -2025
Applications for Nurse Practitioner Practicum 2025
This is open for applications throughout the year. For more information and to apply click HERE
Kia ora koutou
A bit of a mixed bag update but an essential one. Thanks to all who have reached out about the CVD calculator. We have updated the website to prioritise the more accurate and contemporary VAREANZ risk predictor calculator which includes an equation for people with type 2 diabetes. https://nzssd.org.nz/resources/section/calculators
We have been made aware of a number of deep fakes promoting fake "diabetes medications" that are using NZSSD members names, faces, and voices. This is a serious concern that requires wide spread awareness. Attached is our media release and we would appreciate if you can circulate this on your own or your workplaces social media channels. We also strongly recommend that anyone impacted by these deep fakes contact the NZ Police.
Thirdly, we wanted to comment on the extended prescription period from three to twelve months. This will have a positive impact for many people living with diabetes for a range of reasons. It remains important however that clinical decision making is the basis for selecting an appropriate prescribing period and the rationale is communicated clearly to tāngata whaiora to manage any concerns or expectations they may have.
Both the NZSSD executive and I are happy to take any further questions or feedback on these issues.
Ngā mihi,
Jo
Dr Jo McClintock (she/her)
Consultant Clinical Psychologist | Kaimātai Hauora Hinengaro
President - New Zealand Society for the Study of Diabetes
president@nzssd.org.nz
Warning: Fake Videos Targeting People with Type 2 Diabetes
The New Zealand Society for the Study of Diabetes (NZSSD) is warning people with type 2 diabetes to be cautious about health advice on social media, especially videos that appear to be from New Zealand doctors.
Please download the PDF for more information.
Click HERE to view latest newsletter
Click HERE for the latest issue
Welcome to Issue 189 of Diabetes and Obesity Research Review.
With the flu season upon us, this issue includes research reminding us of the importance of ensuring our patients with diabetes get vaccinated!
As usual we have attached the PDF, and you can also view the issue online.
Some of the other highlights include:
We hope you enjoy the papers selected for this issue and find them beneficial to you and your patients. Your feedback and suggestions are always welcome, please continue to send them in.
Kind regards,
Professor Jeremy Krebs
The Diabetes and Related Conditions Prescribing Meeting is an opportunity to receive updates on contemporary clinical management and prescribing in diabetes care, and to connect and network with your peers involved or with an interest in diabetes care. The meeting is open to registered nurses and pharmacists with prescribing current authority and nurse practitioners.
The meeting will be held at the Novotel Hotel, Auckland Airport on Tuesday 5th and Wednesday 6th August, 2025.
Here is the link to the meeting information and registration site:
https://www.eventleaf.com/e/DiabetesPrescribingMeeting2025
Kia ora koutou
You may have seen the announcement from Pharmac this week about funding changes that will come into affect on 1 May 2025. .
Freestyle Libre 2 Plus CGM:
From 1 May 2025, Pharmac will be listing the FreeStyle Libre
2 Plus CGM as a standalone continuous glucose monitor (CGM) alongside the
currently listed FreeStyle Libre 2.
The FreeStyle Libre 2 Plus is more accurate than the previous model, it can
also be used for longer. The size, phone app, reader, adhesive, and application
method are the same as the FreeStyle Libre 2. Everyone who is currently
eligible for a funded FreeStyle Libre 2 will be able to switch to the FreeStyle
Libre 2 Plus.
The FreeStyle Libre 2 Plus can be worn for 15 days - a day longer than the
previous model. Because people can wear it for longer, Pharmac is changing how
many people can get on a prescription from 29 per year to 28 per year. This
aligns the FreeStyle Libre 2 Plus with other CGM's that we fund.
It will be available from 1 May 2025, and the currently funded FreeStyle Libre
2 will be delisted from November 2025.
Please pass this news onto your networks as I appreciate there will be a great
deal of interest in this change.
More information is on Pharmac's website
here.
Insulin Degludec with insulin aspart (Ryzodeg)
Pharmac is funding a new type of insulin (branded as Ryzodeg) for people with diabetes from 1 May 2025.
This is a mix insulin with a longer basal insulin combined with insulin aspart. As you know other mix insulins provided by Novo Nordisk have been phased out (PenMix and Mixtard) or will be in the near future (NovoMix) https://www.pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/insulin
Ryzodeg will be an alternative option that may be beneficial for many people with T2DM.
Read the full details here:
The NZSSD Guidance group will be meeting in early May and will ensure all of our guidance documents are updated, with additional information about Ryzodeg.
Ngā mihi
Rosemary
Dr Rosemary Hall
Endocrinologist, Te Whatu Ora; Wellington and Tairāwhiti
President New Zealand Society for the Study of Diabetes
president@nzssd.org.nz
Secretariat: Secretary@nzssd.org.nz
NZSSD website: www.nzssd.org.nz
Kia ora koutou
You may have seen the notice from Pharmac yesterday allowing new special authority applications for liraglutide (Victoza) from 1 March 2025. We are very pleased that the special authority criteria will be the same as when SA's were suspended in May 2024. This will again allow us to prescribe according to our national guidelines and best practice, and we all know how beneficial this will be for people living with diabetes. We are assured by Pharmac that the intention is for no further suspensions of special authority criteria for GLP-1 agonists to allow ongoing access for those who meet criteria. It is of course important, as previously, that these medications are prescribed only for people with T2DM so that availability continues.
The link to detailed information from Pharmac is:
Decision to enable new people to start treatment withliraglutide for type 2 diabetes
Unfortunately, we don't have such good news regarding the global shortage of Glucagon and the limited allocation to Aotearoa NZ.
Glucagon hydrochloride (Glucagen Hypokit): Supply issue
We will continue to keep you informed as more information becomes available.
Ngā mihi
Rosemary
Dr Rosemary Hall
Endocrinologist, Te Whatu Ora; Wellington and Tairāwhiti
President New Zealand Society for the Study of Diabetes
Click HERE to view this issue online
We know that this decision will also bring some anxiety for
our already stretched health system and workforce. NZSSD will provide as much
clinical and practical support as we can to enable the process to be as
streamlined and equitable as possible. We will keep you informed of education
opportunities and guidelines and welcome widespread discussion and resource
sharing.
I have attached our media release.
Pharmac's information page has details of the revised special authority criteria and processes around transitioning people from Medtronic systems.
|
Ngā mihi
Rosemary
Dr Rosemary HallEndocrinologist
President New Zealand Society for the Study of Diabetes
president@nzssd.org.nz
secretary@nzssd.org.nz
NZSSD website: www.nzssd.org
Please see the attached notice.
We suggest transferring people over to a new insulin well in advance of 30 September, to avoid any supply issues